EP1140039B1 - Transparent transdermal nicotine delivery devices - Google Patents

Transparent transdermal nicotine delivery devices Download PDF

Info

Publication number
EP1140039B1
EP1140039B1 EP99965265A EP99965265A EP1140039B1 EP 1140039 B1 EP1140039 B1 EP 1140039B1 EP 99965265 A EP99965265 A EP 99965265A EP 99965265 A EP99965265 A EP 99965265A EP 1140039 B1 EP1140039 B1 EP 1140039B1
Authority
EP
European Patent Office
Prior art keywords
nicotine
backing
less
transdermal
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP99965265A
Other languages
German (de)
French (fr)
Other versions
EP1140039A1 (en
Inventor
Robert M. Gale
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27381223&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1140039(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alza Corp filed Critical Alza Corp
Priority to EP09174885A priority Critical patent/EP2158903A3/en
Publication of EP1140039A1 publication Critical patent/EP1140039A1/en
Application granted granted Critical
Publication of EP1140039B1 publication Critical patent/EP1140039B1/en
Priority to CY20101100100T priority patent/CY1110643T1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/26—Optical properties
    • A61K2800/262—Transparent; Translucent

Definitions

  • the present invention relates to transdermal delivery devices for administering nicotine for use in smoking cessation treatments.
  • the invention is directed to transdermal nicotine delivery devices which are transparent.
  • transdermal route of parenteral drug delivery provides many advantages over other administration routes.
  • Transdermal systems for delivering a wide variety of drugs or other beneficial agents are described in U.S. Patent Nos. 3,598,122 ; 3,598,123 ; 3,731,683 ; 3,797,494 ; 4,031,894 ; 4,144,317 ; 4,201,211 ; 4,286,592 ; 4,314,557 ; 4,379,454 ; 4,435,180 ; 4,559,222 ; 4,568,343 ; 4,573,995 ; 4,588,580 ; 4,645,502 ; 4,698,062 ; 4,704,282 ; 4,725,272 ; 4,781,924 ; 4,788,062 ; 4,816,258 ; 4,849,226 ; 4,904,475 ; 4,908,027 ; 4,917,895 ; 4,938,759 ; 4,943,435 ; 5,004,610 ; 5,07
  • Nicotine chewing gum and transdermal nicotine are two of the most widely used forms of nicotine replacement therapy currently available.
  • Transdermal devices for administering nicotine are disclosed in U.S. Patent Nos.
  • transdermal drug delivery devices of the prior art utilize an impermeable backing on the skin distal surface of the device to protect the device from damage and to prevent loss of the active ingredient(s).
  • these backing layers are often tinted to a color similar to skin tones.
  • it is not commercially practical to provide pigmented backing layers for transdermal systems which approximate all skin colors.
  • Another approach that has been taken is to provide transparent transdermal systems in which all elements forming a device are sufficiently transparent to permit the natural skin color to be visible through the device.
  • Marketed products which take this approach include the Alora® and Climara® estrogen replacement patches and the Duragesic® transdermal fentanyl delivery system. When these devices are applied to the skin, the patient's natural skin color is visible through the patch, making the presence of the patch extremely inconspicuous. Government regulations require that these products bear identifying indicia, but the indicia can be printed on these devices in light colored or white ink which is not noticeable from a distance of several feet, but is still readable on close inspection.
  • Nicotine is a liquid alkaloid that is colorless, volatile, strongly alkaline, readily oxidized, subject to degradation on exposure to light and highly permeable through not only the human skin, but also many of the polymers conventionally used in the fabrication of backing layers and packaging materials for transdermal products (see for example U.S. Patent 5,077,104 ).
  • the backing layers of the transdermal nicotine delivery devices currently available utilize opaque, skin-colored multilaminate films which typically contain a metallized layer, such as aluminum.
  • transdermal nicotine patches use opaque backings, but many of these devices, due to the complexities of handling and processing nicotine, have other components which are not transparent.
  • the original Prostep® transdermal nicotine product used a drug reservoir in the form of an opaque white gel, held in place by an opaque adhesive overlay.
  • the Habitrol® and Nicotrol® nicotine patches incorporated absorbant pads in the drug reservoir in which the nicotine was absorbed.
  • US patent number 5,626,866 discloses a method for making a transdermal drug delivery device, which device comprises first and second drug permeable adhesive layers containing a drug in gel form.
  • US patent number 5,372,819 discloses a transdermal drug delivery device which comprises a flexible backing which comprises a polymer blend in the form of a film, the blend comprising two forms of low density polyethylene copolymers.
  • EP 0563507A discloses a transdermal patch which comprises a laminate carrier layer and a backing layer, the carrier layer comprising a monolithic carrier layer which comprises an active ingredient melt-blended with a thermoplastic matrix polymer.
  • the present invention relates to a device for the transdermal administration of nicotine comprising a backing layer, a drug reservoir layer containing nicotine carried by said backing layer, and means for maintaining the device in nicotine transmitting relationship with the skin, characterised in that the device absorbs less than 48.6% of incidental light passing through the device so as to permit the natural skin colour of the subject to whom the device is applied to be visible through said device, and in that the device is effective for nicotine replacement therapy for 16-24 hours under exposure of the device to light, wherein the backing is formed from a PET/EVA laminate.
  • the backing of the device may have a nicotine permeability of less than 1.0 ⁇ g/cm 2 .hr.
  • the backing of the device may have a nicotine permeability of less than 0.5pg/cm 2 .hr.
  • the backing of the device may have a solubility for nicotine of less than 1 wt%.
  • the backing of the device may have a solubility for nicotine of less than 0.1 wt%.
  • the device may absorb less than 35.11% of incidental light passing through the device.
  • the device may absorb less than 20% of incidental light passing through the device.
  • Preferred devices of this invention utilize, as the backing layer, a transparent polymeric film which has a permeability to nicotine of less than 1 ⁇ g/cm 2 ⁇ hr, preferably less than 0.5 ⁇ g /cm 2 ⁇ hr, a solubility for nicotine that is less than 1% by weight and preferably less than 0.1 %.
  • Such films are preferably less than 0.15mm (6 mils) thick and most preferably 0.05-0.1mm (2-4 mils) thick.
  • Such films are used in combination with one or more of the conventional elements of a transdermal device (other than the removable release liner) such as the drug reservoir, adhesive and rate controlling membranes, which must also be sufficiently transparent as to permit the natural skin color to be clearly visible through the assembled device after placement on the skin.
  • the finished product absorbs less than 48.6% of incidental light passing through it, preferably less than 35.11% and more preferably less than 20%.
  • the backing layer In addition to being transparent and being sufficiently impermeable to nicotine, the backing layer must also have sufficient mechanical strength and physical integrity to maintain the system intact throughout its intended administration period, which is typically 16-24 hours, and must provide a stable interface with adjoining layers such as the drug reservoir or adhesive layers of the transdermal device. This combination of properties is not always found in one material, and thus the transparent backing layers used on the devices of this invention can be multilaminate films.
  • a backing layer In addition to having a low permeability to nicotine, a backing layer must also have a low solubility for nicotine. This is because nicotine is toxic and it could be dangerous for a child, for example, to lick the backing layer if it contained a substantial amount of dissolved nicotine.
  • Suitable polymer materials possessing properties required by this invention include Scotchpak® 1220 which is a polyethylene terephtalate /ethylene vinyl acetate (PET EVA), bilaminate film sold by the 3M Company, Minneapolis, Minnesota.
  • Scotchpak® 1220 which is a polyethylene terephtalate /ethylene vinyl acetate (PET EVA), bilaminate film sold by the 3M Company, Minneapolis, Minnesota.
  • the transparent transdermal delivery devices of this invention can be of any of the forms described in the aforementioned patents.
  • the preferred form comprises a laminate of the backing layer, a nicotine reservoir layer which contains nicotine dissolved in a carrier at a concentration below the saturation concentration of nicotine in the carrier.
  • the drug reservoir component is self adhesive, a simple monolithic device could be employed.
  • additional components such as rate controlling membranes, and a separate adhesive layer for maintaining the devices on the skin such as is described in U.S. Patents 5,004,610 and 5,342,623 listed above.
  • the device may also contain other drugs or other active substances which cooperate with or enhance the effect of nicotine in smoking cessation, smoking replacement or smoking substitution therapy.
  • a removable release liner would normally be applied on the adhesive surface of the patch that is used to keep the device on the skin, which release liner is removed prior to use.
  • the adhesive component is preferably a pressure sensitive adhesive including, but not limited to, polysiloxanes, polyacrylates, polyurethanes, acrylic adhesives including cross linked or uncross linked acrylic copolymers, vinyl acetate adhesives, ethylene vinylacetate copolymers, and natural or synthetic rubbers including polybutadienes, polyisoprenes, and polyisobutylene adhesives, and mixtures and graft copolymers thereof.
  • the devices may also be provided with hydrophilic water absorbing polymers known in the art such as polyvinyl alcohol and polyvinyl pyrolidone individually or in combination.
  • the adhesive can be used to form a monolithic delivery device in which the nicotine is dissolved in the adhesive to form a self-adhesive drug reservoir.
  • the adhesive can be applied to the surface of a non-adhesive reservoir in which nicotine is dissolved, to form a multilaminate device.
  • a rate-controlled membrane can also be interfaced between the nicotine reservoir and the adhesive, as is known to the art.
  • the nicotine can be administered in combination with another agent which could include anti-anxiolytics, antihypertensives, antidepressants, and appetite suppressants, such as fluoxetine, caffeine, buspirone, phenylpropanolamine, clonidine, paroxetine, citalopram, and sertraline.
  • anti-anxiolytics such as fluoxetine, caffeine, buspirone, phenylpropanolamine, clonidine, paroxetine, citalopram, and sertraline.
  • the nicotine in the device is present in the reservoir at a subsaturated condition (i.e. less than unit activity) such that no undissolved nicotine is present in the reservoir. If other agents are present in the device, they are preferably present fully dissolved, but can be present in undissolved form so long as the end product displays the proper degree of transparency.
  • nicotine and optionally other agents to be coadministered are delivered through the skin or other body surface at a therapeutically effective rate for a predetermined time period which for nicotine is preferably 16-24 hours.
  • transdermal therapeutic devices of the present invention are prepared in a manner known in the art, such as by those procedures described in the transdermal device patents listed previously herein.
  • transdermal patches were tested to determine their transparency and compared to the transparent nicotine patches according to this invention.
  • the nicotine patches were prepared as set forth in Example IV of U.S. Patent No. 5,004,610 with a PET/EVA (Scotchpak® 1220, 3M, Minneapolis, MN) or Saranex® (Dow Chemical Company, Midland, MI) backing substituted for the Scotchpak 1006 backing.
  • the light transmitted through the various systems was measured by a Macbeth 1500/Plus color measurement system (Kollmorgem Instruments Corp., Newburgh, NY). Table 1 shows the Opacity Index, which is the percentage of incidental light which is absorbed by passage through the device, for the various systems tested.
  • transdermal devices according to this invention have an Opacity Index less than 48.6%, preferably less than 35.11%, more preferably less than 20%.

Abstract

A device for the transdermal administration of nicotine comprises a backing layer, a drug reservoir layer containing nicotine carried by said backing layer, and means for maintaining the device in nicotine transmitting relationship with the skin. The the device absorbs less than 48.6% of incidental light passing through the device so as to permit the natural skin colour of the subject to whom the device is applied to be visible through said device, and is effective for nicotine replacement therapy under exposure of the device to light.

Description

    Field of the Invention
  • The present invention relates to transdermal delivery devices for administering nicotine for use in smoking cessation treatments. In particular, the invention is directed to transdermal nicotine delivery devices which are transparent.
    • Background of the Invention
  • The administration of nicotine buccally, nasally and transdermally to assist a patient desiring to quit smoking has been shown to be clinically effective in reducing the rate of recidivism. Nicotine chewing gum and transdermal nicotine are two of the most widely used forms of nicotine replacement therapy currently available. Transdermal devices for administering nicotine are disclosed in U.S. Patent Nos. 4,597,961 ; 4,758,434 ; 4,764,382 ; 4,839,174 ; 4,908,213 ; 4,915,950 ; 4,943,435 ; 4,946,853 ; 5,004,610 ; 5,016,652 ; 5,077,104 ; 5,230,896 ; 5,411,739 ; 5,462,745 ; 5,508,038 ; 5,599,554 ; 5,603,947 and 5,726,190 , for example.
  • Most of the transdermal drug delivery devices of the prior art utilize an impermeable backing on the skin distal surface of the device to protect the device from damage and to prevent loss of the active ingredient(s). In order to improve user satisfaction, these backing layers are often tinted to a color similar to skin tones. However, as can be readily appreciated, it is not commercially practical to provide pigmented backing layers for transdermal systems which approximate all skin colors.
  • Another approach that has been taken is to provide transparent transdermal systems in which all elements forming a device are sufficiently transparent to permit the natural skin color to be visible through the device. Marketed products which take this approach include the Alora® and Climara® estrogen replacement patches and the Duragesic® transdermal fentanyl delivery system. When these devices are applied to the skin, the patient's natural skin color is visible through the patch, making the presence of the patch extremely inconspicuous. Government regulations require that these products bear identifying indicia, but the indicia can be printed on these devices in light colored or white ink which is not noticeable from a distance of several feet, but is still readable on close inspection.
  • Such transparent patches have been found useful with non-volatile drugs such as fentanyl and hormone replacement steroids, but no such transparent product has been developed for the delivery of nicotine.
  • Nicotine is a liquid alkaloid that is colorless, volatile, strongly alkaline, readily oxidized, subject to degradation on exposure to light and highly permeable through not only the human skin, but also many of the polymers conventionally used in the fabrication of backing layers and packaging materials for transdermal products (see for example U.S. Patent 5,077,104 ). As a result, the backing layers of the transdermal nicotine delivery devices currently available utilize opaque, skin-colored multilaminate films which typically contain a metallized layer, such as aluminum.
  • Not only do the commercially available transdermal nicotine patches use opaque backings, but many of these devices, due to the complexities of handling and processing nicotine, have other components which are not transparent. For example, the original Prostep® transdermal nicotine product used a drug reservoir in the form of an opaque white gel, held in place by an opaque adhesive overlay. The Habitrol® and Nicotrol® nicotine patches incorporated absorbant pads in the drug reservoir in which the nicotine was absorbed.
  • It has also been proposed to co-administer nicotine with other substances that improve nicotine cessation therapy. See, for example, patents 4,908,213 ; 5,599,554 ; and 5,726,190 noted above, and WO 97/33581 .
  • US patent number 5,626,866 discloses a method for making a transdermal drug delivery device, which device comprises first and second drug permeable adhesive layers containing a drug in gel form.
  • US patent number 5,372,819 discloses a transdermal drug delivery device which comprises a flexible backing which comprises a polymer blend in the form of a film, the blend comprising two forms of low density polyethylene copolymers.
  • EP 0563507A discloses a transdermal patch which comprises a laminate carrier layer and a backing layer, the carrier layer comprising a monolithic carrier layer which comprises an active ingredient melt-blended with a thermoplastic matrix polymer.
    • SUMMARY OF THE INVENTION
  • The present invention relates to a device for the transdermal administration of nicotine comprising a backing layer, a drug reservoir layer containing nicotine carried by said backing layer, and means for maintaining the device in nicotine transmitting relationship with the skin, characterised in that the device absorbs less than 48.6% of incidental light passing through the device so as to permit the natural skin colour of the subject to whom the device is applied to be visible through said device, and in that the device is effective for nicotine replacement therapy for 16-24 hours under exposure of the device to light, wherein the backing is formed from a PET/EVA laminate.
  • Preferably the backing of the device may have a nicotine permeability of less than 1.0µg/cm2 .hr.
  • More preferably the backing of the device may have a nicotine permeability of less than 0.5pg/cm2 .hr.
  • Preferably the backing of the device may have a solubility for nicotine of less than 1 wt%.
  • More preferably the backing of the device may have a solubility for nicotine of less than 0.1 wt%.
  • Preferably the device may absorb less than 35.11% of incidental light passing through the device.
  • More preferably the device may absorb less than 20% of incidental light passing through the device.
    • DETAILED DESCRIPTION OF THE INVENTION
  • Preferred devices of this invention utilize, as the backing layer, a transparent polymeric film which has a permeability to nicotine of less than 1 µg/cm2 · hr, preferably less than 0.5 µg /cm2 · hr, a solubility for nicotine that is less than 1% by weight and preferably less than 0.1 %. Such films are preferably less than 0.15mm (6 mils) thick and most preferably 0.05-0.1mm (2-4 mils) thick. Such films are used in combination with one or more of the conventional elements of a transdermal device (other than the removable release liner) such as the drug reservoir, adhesive and rate controlling membranes, which must also be sufficiently transparent as to permit the natural skin color to be clearly visible through the assembled device after placement on the skin. The finished product absorbs less than 48.6% of incidental light passing through it, preferably less than 35.11% and more preferably less than 20%.
  • In addition to being transparent and being sufficiently impermeable to nicotine, the backing layer must also have sufficient mechanical strength and physical integrity to maintain the system intact throughout its intended administration period, which is typically 16-24 hours, and must provide a stable interface with adjoining layers such as the drug reservoir or adhesive layers of the transdermal device. This combination of properties is not always found in one material, and thus the transparent backing layers used on the devices of this invention can be multilaminate films. In addition to having a low permeability to nicotine, a backing layer must also have a low solubility for nicotine. This is because nicotine is toxic and it could be dangerous for a child, for example, to lick the backing layer if it contained a substantial amount of dissolved nicotine.
  • Suitable polymer materials possessing properties required by this invention include Scotchpak® 1220 which is a polyethylene terephtalate /ethylene vinyl acetate (PET EVA), bilaminate film sold by the 3M Company, Minneapolis, Minnesota.
  • The transparent transdermal delivery devices of this invention can be of any of the forms described in the aforementioned patents. The preferred form, however, comprises a laminate of the backing layer, a nicotine reservoir layer which contains nicotine dissolved in a carrier at a concentration below the saturation concentration of nicotine in the carrier. If the drug reservoir component is self adhesive, a simple monolithic device could be employed. However, in many cases it is desirable to include additional components such as rate controlling membranes, and a separate adhesive layer for maintaining the devices on the skin such as is described in U.S. Patents 5,004,610 and 5,342,623 listed above. It is further contemplated that in addition to nicotine, the device may also contain other drugs or other active substances which cooperate with or enhance the effect of nicotine in smoking cessation, smoking replacement or smoking substitution therapy. For all these devices, a removable release liner would normally be applied on the adhesive surface of the patch that is used to keep the device on the skin, which release liner is removed prior to use.
  • Various materials suited for fabrication of the various components are known in the art and are disclosed in the aforementioned patents.
  • The adhesive component is preferably a pressure sensitive adhesive including, but not limited to, polysiloxanes, polyacrylates, polyurethanes, acrylic adhesives including cross linked or uncross linked acrylic copolymers, vinyl acetate adhesives, ethylene vinylacetate copolymers, and natural or synthetic rubbers including polybutadienes, polyisoprenes, and polyisobutylene adhesives, and mixtures and graft copolymers thereof. The devices may also be provided with hydrophilic water absorbing polymers known in the art such as polyvinyl alcohol and polyvinyl pyrolidone individually or in combination. The adhesive can be used to form a monolithic delivery device in which the nicotine is dissolved in the adhesive to form a self-adhesive drug reservoir. Alternatively, the adhesive can be applied to the surface of a non-adhesive reservoir in which nicotine is dissolved, to form a multilaminate device. A rate-controlled membrane can also be interfaced between the nicotine reservoir and the adhesive, as is known to the art.
  • The nicotine can be administered in combination with another agent which could include anti-anxiolytics, antihypertensives, antidepressants, and appetite suppressants, such as fluoxetine, caffeine, buspirone, phenylpropanolamine, clonidine, paroxetine, citalopram, and sertraline.
  • The nicotine in the device is present in the reservoir at a subsaturated condition (i.e. less than unit activity) such that no undissolved nicotine is present in the reservoir. If other agents are present in the device, they are preferably present fully dissolved, but can be present in undissolved form so long as the end product displays the proper degree of transparency.
  • In the present invention, nicotine and optionally other agents to be coadministered are delivered through the skin or other body surface at a therapeutically effective rate for a predetermined time period which for nicotine is preferably 16-24 hours.
  • The transdermal therapeutic devices of the present invention are prepared in a manner known in the art, such as by those procedures described in the transdermal device patents listed previously herein.
  • The following example is offered to illustrate the practice of the present invention.
    • EXAMPLE 1
  • Various commercially available transdermal patches were tested to determine their transparency and compared to the transparent nicotine patches according to this invention. The nicotine patches were prepared as set forth in Example IV of U.S. Patent No. 5,004,610 with a PET/EVA (Scotchpak® 1220, 3M, Minneapolis, MN) or Saranex® (Dow Chemical Company, Midland, MI) backing substituted for the Scotchpak 1006 backing. The light transmitted through the various systems was measured by a Macbeth 1500/Plus color measurement system (Kollmorgem Instruments Corp., Newburgh, NY). Table 1 shows the Opacity Index, which is the percentage of incidental light which is absorbed by passage through the device, for the various systems tested. Table 1: Patch Opacity
    Patch Opacity Index
    Minitran® 48.6%
    Alora® 20.21%
    FemPatch® 35.11%
    Climara® 19.33%
    Ex. 1 - Nicotine with Saranex® backing 17.04%
    Ex. 1 - Nicotine with PET/EVA backing 19.66%
  • The Minitran® nitroglycerine system is clearly visible from a distance of about 5 feet, whereas the FemPatch® is significantly less noticeable. The Alora®, Climara® and Nicoderm® patches, however, are extremely inconspicuous. Accordingly, transdermal devices according to this invention
    have an Opacity Index less than 48.6%, preferably less than 35.11%, more preferably less than 20%.

Claims (7)

  1. A device for the transdermal administration of nicotine comprising a backing layer, a drug reservoir layer containing nicotine carried by said backing layer, and means for maintaining the device in nicotine transmitting relationship with the skin, characterised in that the device absorbs less than 48.6% of incidental light passing through the device so as to permit the natural skin colour of the subject to whom the device is applied to be visible through said device, and in that the device is effective for nicotine replacement therapy for 16-24 hours under exposure of the device to light, wherein the backing is formed from a PET/EVA laminate.
  2. A device according to claim 1 wherein said backing has a nicotine permeability of less than 1.0µg/cm2 .hr.
  3. A device according to claim 2 wherein the backing has a nicotine permeability of less than 0.5µg/cm2 .hr.
  4. A device according to claim 1, 2 or 3 wherein the backing has a solubility for nicotine of less than 1 wt%.
  5. A device according to claim 4 wherein the backing has a solubility for nicotine of less than 0.1 wt%.
  6. A device according to any preceding claim wherein the device absorbs less than 35.11% of incidental light passing through the device.
  7. A device according to claim 6 wherein the device absorbs less than 20% of incidental light passing through the device.
EP99965265A 1998-12-18 1999-12-14 Transparent transdermal nicotine delivery devices Expired - Lifetime EP1140039B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP09174885A EP2158903A3 (en) 1998-12-18 1999-12-14 Transparent Transdermal Nicotine Delivery Devices
CY20101100100T CY1110643T1 (en) 1998-12-18 2010-02-03 NICOTININ TRANSPARENT TRANSLATOR APPLIANCES

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US11273098P 1998-12-18 1998-12-18
US112730P 1998-12-18
US12467999P 1999-03-16 1999-03-16
US124679P 1999-03-16
US12679899P 1999-03-30 1999-03-30
US126798P 1999-03-30
PCT/US1999/029731 WO2000037058A1 (en) 1998-12-18 1999-12-14 Transparent transdermal nicotine delivery devices

Publications (2)

Publication Number Publication Date
EP1140039A1 EP1140039A1 (en) 2001-10-10
EP1140039B1 true EP1140039B1 (en) 2009-11-04

Family

ID=27381223

Family Applications (2)

Application Number Title Priority Date Filing Date
EP99965265A Expired - Lifetime EP1140039B1 (en) 1998-12-18 1999-12-14 Transparent transdermal nicotine delivery devices
EP09174885A Withdrawn EP2158903A3 (en) 1998-12-18 1999-12-14 Transparent Transdermal Nicotine Delivery Devices

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP09174885A Withdrawn EP2158903A3 (en) 1998-12-18 1999-12-14 Transparent Transdermal Nicotine Delivery Devices

Country Status (23)

Country Link
US (6) US7622136B2 (en)
EP (2) EP1140039B1 (en)
JP (1) JP4864204B2 (en)
KR (1) KR100603168B1 (en)
CN (2) CN101693023A (en)
AT (1) ATE447398T1 (en)
AU (1) AU774594B2 (en)
BR (1) BR9916214A (en)
CA (1) CA2354621C (en)
CY (1) CY1110643T1 (en)
CZ (1) CZ302035B6 (en)
DE (1) DE69941629D1 (en)
DK (1) DK1140039T3 (en)
ES (1) ES2336054T3 (en)
HK (1) HK1040915B (en)
HU (1) HUP0104728A3 (en)
IL (2) IL143778A0 (en)
NO (1) NO332084B1 (en)
NZ (1) NZ512432A (en)
PL (1) PL195871B1 (en)
PT (1) PT1140039E (en)
TR (1) TR200101783T2 (en)
WO (1) WO2000037058A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1140039T3 (en) 1998-12-18 2010-03-22 Alza Corp Transparent devices for percutaneous nicotine administration
DE10018834A1 (en) * 2000-04-15 2001-10-25 Lohmann Therapie Syst Lts Transdermal or transmucosal pharmaceutical dosage form for treatment of nicotine dependence or smoking withdrawal contains nicotine compound or substitute and CNS active compound
DE10317692A1 (en) 2003-04-17 2004-11-11 Lts Lohmann Therapie-Systeme Ag Medical active substance patches with reduced optical conspicuity on the skin
DE102005010255A1 (en) * 2005-03-07 2006-09-14 Lts Lohmann Therapie-Systeme Ag Fiber-free transdermal therapeutic system and method for its production
US20070098772A1 (en) * 2005-09-23 2007-05-03 Westcott Tyler D Transdermal norelgestromin delivery system
EP2308480B1 (en) * 2005-09-23 2014-08-13 ALZA Corporation High Enhancer-Loading Polyacrylate Formulation for Transdermal Applications
ES2499067T3 (en) 2005-10-13 2014-09-26 Nitto Denko Corporation Transdermal preparation of nicotine and its production method
AR071420A1 (en) 2008-05-01 2010-06-16 Smithkline Beecham Corp COMPOSITION OF PILL FOR ORAL SHOOTING THAT INCLUDES AN ACTIVE PRINCIPLE OF NICOTINE AND PROCEDURE FOR MANUFACTURING IT
DE102010053792A1 (en) 2010-12-08 2012-06-14 Frank Becher Device for germ-free keeping of surfaces, such as door handles, handrails, grip bars, handles of shopping carts and toilet seating surfaces, has flat support material and self-adhesive portion formed on one side of flat support material
DE102011080390B3 (en) * 2011-08-03 2012-07-12 Acino Ag application aid
GB2503939A (en) * 2012-07-13 2014-01-15 Kind Consumer Ltd Products derived from tobaccco biomass
WO2015089310A1 (en) * 2013-12-11 2015-06-18 Atkinson Oscar Occlusive skin covering
EP3730128A4 (en) * 2017-12-20 2021-08-04 Easting Biotech Company Limited Pasting structure
US20220160647A1 (en) * 2020-11-24 2022-05-26 First Necessity, LLC Transdermal drug delivery device/transdermal patch and other applications of emulsion formulation

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US498062A (en) * 1893-05-23 Method of converting iron into steel
US645502A (en) * 1898-10-28 1900-03-13 Lewis A Carpenter Repair-plug for pneumatic tires.
US3797494A (en) 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3598122A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3995631A (en) 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US3731683A (en) 1971-06-04 1973-05-08 Alza Corp Bandage for the controlled metering of topical drugs to the skin
US4144317A (en) 1975-05-30 1979-03-13 Alza Corporation Device consisting of copolymer having acetoxy groups for delivering drugs
US4031894A (en) 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
DE2644323C3 (en) * 1976-10-01 1980-03-20 Metallgesellschaft Ag, 6000 Frankfurt Process for the regeneration of water-containing, volatile organic solvents which are used to wash out acidic gas components from low-water gases with low contents of volatile compounds of metals of the 8th group
US4201211A (en) 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
JPS5522535A (en) * 1978-08-04 1980-02-18 Bridgestone Corp Heavy vehicle pneumatic tire
US4203440A (en) 1978-10-23 1980-05-20 Alza Corporation Device having variable volume chamber for dispensing useful agent
JPS5632414A (en) * 1979-08-28 1981-04-01 Suzuki Nihondou:Kk Preparation of stretchable clear sticking plaster
US4286592A (en) 1980-02-04 1981-09-01 Alza Corporation Therapeutic system for administering drugs to the skin
US4314557A (en) 1980-05-19 1982-02-09 Alza Corporation Dissolution controlled active agent dispenser
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4379454A (en) 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
JPS6244654Y2 (en) * 1981-04-11 1987-11-26
US4725272A (en) 1981-06-29 1988-02-16 Alza Corporation Novel bandage for administering beneficial drug
US4849226A (en) 1981-06-29 1989-07-18 Alza Corporation Method for increasing oxygen supply by administering vasodilator
US4373454A (en) * 1981-08-28 1983-02-15 The United States Of America As Represented By The Department Of Energy Oil shale retorting and combustion system
US4435180A (en) 1982-05-25 1984-03-06 Alza Corporation Elastomeric active agent delivery system and method of use
US4559222A (en) 1983-05-04 1985-12-17 Alza Corporation Matrix composition for transdermal therapeutic system
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
JPS6069014A (en) 1983-09-27 1985-04-19 Nitto Electric Ind Co Ltd Patch for curing dermatopathy
AU591171B2 (en) 1983-11-02 1989-11-30 Alza Corporation Dispenser for delivering thermo-responsive composition
US4627850A (en) 1983-11-02 1986-12-09 Alza Corporation Osmotic capsule
US4704282A (en) 1984-06-29 1987-11-03 Alza Corporation Transdermal therapeutic system having improved delivery characteristics
US4588580B2 (en) 1984-07-23 1999-02-16 Alaz Corp Transdermal administration of fentanyl and device therefor
DE3586707T2 (en) 1984-10-05 1993-02-11 Hercon Lab SYSTEM FOR TRANSDERMAL APPLICATION OF A MEDICINAL PRODUCT.
US4573995A (en) 1984-10-09 1986-03-04 Alza Corporation Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine
US4568343A (en) 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
EP0184910B1 (en) 1984-11-15 1992-09-30 Hercon Laboratories Corporation Device for controlled release drug delivery
US4597961A (en) 1985-01-23 1986-07-01 Etscorn Frank T Transcutaneous application of nicotine
US5016652A (en) 1985-04-25 1991-05-21 The Regents Of The University Of California Method and apparatus for aiding in the reduction of incidence of tobacco smoking
US4645502A (en) 1985-05-03 1987-02-24 Alza Corporation Transdermal delivery of highly ionized fat insoluble drugs
US4904475A (en) 1985-05-03 1990-02-27 Alza Corporation Transdermal delivery of drugs from an aqueous reservoir
US4698062A (en) 1985-10-30 1987-10-06 Alza Corporation Medical device for pulsatile transdermal delivery of biologically active agents
US4710191A (en) 1985-12-16 1987-12-01 Jonergin, Inc. Therapeutic device for the administration of medicaments
US5316759A (en) 1986-03-17 1994-05-31 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
EP0249343B1 (en) 1986-06-13 1992-01-08 Alza Corporation Moisture activation of transdermal drug delivery system
US4938759A (en) 1986-09-02 1990-07-03 Alza Corporation Transdermal delivery device having a rate controlling adhesive
US4908027A (en) 1986-09-12 1990-03-13 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
US5344656A (en) * 1986-09-12 1994-09-06 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
US4816258A (en) 1987-02-26 1989-03-28 Alza Corporation Transdermal contraceptive formulations
US4788062A (en) 1987-02-26 1988-11-29 Alza Corporation Transdermal administration of progesterone, estradiol esters, and mixtures thereof
US5071656A (en) 1987-03-05 1991-12-10 Alza Corporation Delayed onset transdermal delivery device
IL86170A (en) 1987-05-01 1992-12-01 Elan Transdermal Ltd Preparations and compositions comprising nicotine for percutaneous administration
DE3743947A1 (en) 1987-09-01 1989-03-09 Lohmann Gmbh & Co Kg DEVICE FOR THE CONTROLLED DELIVERY OF NICOTIN, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE
US4943435A (en) 1987-10-05 1990-07-24 Pharmetrix Corporation Prolonged activity nicotine patch
US4839174A (en) 1987-10-05 1989-06-13 Pharmetrix Corporation Novel transdermal nicotine patch
US4917895A (en) 1987-11-02 1990-04-17 Alza Corporation Transdermal drug delivery device
US4781924A (en) 1987-11-09 1988-11-01 Alza Corporation Transdermal drug delivery device
US4915895A (en) * 1987-11-30 1990-04-10 General Motors Corporation Method for making a composite tread for track-laying vehicles
US4915950A (en) 1988-02-12 1990-04-10 Cygnus Research Corporation Printed transdermal drug delivery device
US4840796A (en) 1988-04-22 1989-06-20 Dow Corning Corporation Block copolymer matrix for transdermal drug release
US5364630A (en) * 1988-06-14 1994-11-15 Alza Corporation Subsaturated nicotine transdermal therapeutic system
US5004610A (en) 1988-06-14 1991-04-02 Alza Corporation Subsaturated nicotine transdermal therapeutic system
US5167649A (en) * 1988-08-22 1992-12-01 Zook Gerald P Drug delivery system for the removal of dermal lesions
US4908213A (en) 1989-02-21 1990-03-13 Schering Corporation Transdermal delivery of nicotine
US5230896A (en) 1989-10-12 1993-07-27 Warner-Lambert Company Transdermal nicotine delivery system
SE8904296D0 (en) 1989-12-21 1989-12-21 Pharmacia Ab TRANSDERMAL SYSTEM
US5077104A (en) * 1989-12-21 1991-12-31 Alza Corporation Nicotine packaging materials
US5324280A (en) 1990-04-02 1994-06-28 Alza Corporation Osmotic dosage system for delivering a formulation comprising liquid carrier and drug
US5508038A (en) 1990-04-16 1996-04-16 Alza Corporation Polyisobutylene adhesives for transdermal devices
US5314694A (en) 1990-10-29 1994-05-24 Alza Corporation Transdermal formulations, methods and devices
US5122382A (en) 1990-10-29 1992-06-16 Alza Corporation Transdermal contraceptive formulations, methods and devices
JP3067114B2 (en) * 1991-06-04 2000-07-17 ソニー株式会社 Micro lens formation method
JPH0523925A (en) 1991-07-19 1993-02-02 Mazda Motor Corp Floating support mechanism in part assembly device
US6010715A (en) * 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
CA2075517C (en) * 1992-04-01 1997-03-11 John Wick Transdermal patch incorporating a polymer film incorporated with an active agent
ATE185694T1 (en) 1992-05-13 1999-11-15 Alza Corp OXYBUTYNIN FOR TRANSDERMAL ADMINISTRATION
US5264219A (en) * 1992-08-07 1993-11-23 Minnesota Mining And Manufacturing Company Transdermal drug delivery backing
JPH09505028A (en) 1993-07-09 1997-05-20 シグナス，インコーポレイテッド Methods and devices for providing percutaneous / buccal nicotine replacement therapy
US5362496A (en) * 1993-08-04 1994-11-08 Pharmetrix Corporation Method and therapeutic system for smoking cessation
JPH07165563A (en) * 1993-12-08 1995-06-27 Sekisui Chem Co Ltd Tape pharmaceutical preparation
AU676430B2 (en) * 1994-03-07 1997-03-06 Theratech, Inc. Drug-containing adhesive composite transdermal delivery device
WO1996000072A1 (en) 1994-06-23 1996-01-04 The Procter & Gamble Company Treatment of nicotine craving and/or smoking withdrawal symptoms with a transdermal or transmucosal composition containing nicotine and caffeine or xanthine
US5635203A (en) 1994-09-29 1997-06-03 Alza Corporation Transdermal device having decreased delamination
EP0828489A4 (en) 1996-03-13 2001-04-04 Univ Yale Smoking cessation treatments using naltrexone and related compounds
CA2250025C (en) 1996-03-25 2006-10-31 Lts Lohmann Therapie-Systeme Gmbh Transdermal therapeutic system with small application-area thickness and great flexibility, and production process
JPH09323925A (en) * 1996-06-03 1997-12-16 Sekisui Chem Co Ltd Plaster
GR1002807B (en) * 1996-06-20 1997-11-13 Lavipharm A.E. Device for topical treatment of acne and method of manufacture.
US6512010B1 (en) * 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
IT1289160B1 (en) 1997-01-08 1998-09-29 Jagotec Ag FULLY COATED PHARMACEUTICAL TABLET FOR THE CONTROLLED RELEASE OF ACTIVE INGREDIENTS WHICH PRESENT PROBLEMS OF
US6203817B1 (en) * 1997-02-19 2001-03-20 Alza Corporation Reduction of skin reactions caused by transdermal drug delivery
JPH10279472A (en) * 1997-04-02 1998-10-20 Oji Paper Co Ltd Plaster for external use
DE69833000T2 (en) * 1997-09-26 2006-09-07 Noven Pharmaceuticals, Inc., Miami BIO-ADHESIVE COMPOSITIONS
US6013722A (en) 1998-01-27 2000-01-11 3M Innovative Properties Company Non-whitening emulsion pressure sensitive adhesives
FR2778560B1 (en) * 1998-05-12 2001-06-01 Oreal USE OF CINNAMIC ACID OR AT LEAST ONE OF ITS DERIVATIVES IN A COMPOSITION FOR PROMOTING DEQUAMATION OF THE SKIN, AND COMPOSITION COMPRISING SAME
DK1140039T3 (en) 1998-12-18 2010-03-22 Alza Corp Transparent devices for percutaneous nicotine administration
CN102736278B (en) 2011-04-01 2014-12-17 纬创资通股份有限公司 Liquid crystal display device and electronic device comprising same

Also Published As

Publication number Publication date
EP1140039A1 (en) 2001-10-10
PL195871B1 (en) 2007-11-30
CN101693023A (en) 2010-04-14
US20120310187A1 (en) 2012-12-06
US20140180223A1 (en) 2014-06-26
US20080031933A1 (en) 2008-02-07
KR20010084881A (en) 2001-09-06
EP2158903A3 (en) 2010-04-14
HUP0104728A2 (en) 2002-05-29
ATE447398T1 (en) 2009-11-15
NO20013012L (en) 2001-06-18
US20150164820A1 (en) 2015-06-18
US20040234585A1 (en) 2004-11-25
US7622136B2 (en) 2009-11-24
JP4864204B2 (en) 2012-02-01
WO2000037058A1 (en) 2000-06-29
JP2002532540A (en) 2002-10-02
BR9916214A (en) 2001-09-11
CY1110643T1 (en) 2015-04-29
CA2354621A1 (en) 2000-06-29
AU774594B2 (en) 2004-07-01
PT1140039E (en) 2010-02-03
IL143778A (en) 2008-03-20
CA2354621C (en) 2009-09-29
EP2158903A2 (en) 2010-03-03
HK1040915A1 (en) 2002-06-28
CN1331586A (en) 2002-01-16
NZ512432A (en) 2003-10-31
DE69941629D1 (en) 2009-12-17
NO332084B1 (en) 2012-06-18
HK1040915B (en) 2010-05-07
US8075911B2 (en) 2011-12-13
DK1140039T3 (en) 2010-03-22
US8999379B2 (en) 2015-04-07
NO20013012D0 (en) 2001-06-18
CZ20012230A3 (en) 2001-10-17
KR100603168B1 (en) 2006-07-24
US20160058747A1 (en) 2016-03-03
HUP0104728A3 (en) 2006-07-28
ES2336054T3 (en) 2010-04-07
TR200101783T2 (en) 2002-05-21
IL143778A0 (en) 2002-04-21
CZ302035B6 (en) 2010-09-15
US9205059B2 (en) 2015-12-08
US8663680B2 (en) 2014-03-04
PL348337A1 (en) 2002-05-20
AU3121700A (en) 2000-07-12

Similar Documents

Publication Publication Date Title
US9205059B2 (en) Transparent transdermal nicotine delivery devices
AU640383B2 (en) Resilient transdermal drug-delivery device and compositions and devices employing fatty acid esters/ethers of alkanediolsas percutaneous absorption enhancers
CA2064765C (en) Biphasic transdermal drug delivery device
US4588580A (en) Transdermal administration of fentanyl and device therefor
US4906463A (en) Transdermal drug-delivery composition
US6440453B1 (en) Transdermal systems for release of 5-HT3 receptor antagonists and their use in anti-emetic treatment
JP2002532540A5 (en)
KR20020084161A (en) Transdermal therapeutic system for the delivery of lerisetron
RU2246937C2 (en) System for transcutaneous administration of nicotine(85)18.06.2001
MXPA01006199A (en) Transparent transdermal nicotine delivery devices
EP1196151B1 (en) Transdermal therapeutic system for administering a calcium antagonist
CN112807290A (en) Novel scopolamine transdermal drug delivery patch

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010718

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17Q First examination report despatched

Effective date: 20020715

17Q First examination report despatched

Effective date: 20020715

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69941629

Country of ref document: DE

Date of ref document: 20091217

Kind code of ref document: P

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20100127

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: DR. LUSUARDI AG

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Ref country code: GR

Ref legal event code: EP

Ref document number: 20100400249

Country of ref document: GR

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2336054

Country of ref document: ES

Kind code of ref document: T3

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1040915

Country of ref document: HK

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

26 Opposition filed

Opponent name: BECHER, FRANK

Effective date: 20100701

PLAX Notice of opposition and request to file observation + time limit sent

Free format text: ORIGINAL CODE: EPIDOSNOBS2

PLBB Reply of patent proprietor to notice(s) of opposition received

Free format text: ORIGINAL CODE: EPIDOSNOBS3

PLCK Communication despatched that opposition was rejected

Free format text: ORIGINAL CODE: EPIDOSNREJ1

PLBN Opposition rejected

Free format text: ORIGINAL CODE: 0009273

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: OPPOSITION REJECTED

27O Opposition rejected

Effective date: 20121204

REG Reference to a national code

Ref country code: DE

Ref legal event code: R100

Ref document number: 69941629

Country of ref document: DE

Effective date: 20121204

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 18

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20181126

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20181211

Year of fee payment: 20

Ref country code: AT

Payment date: 20181126

Year of fee payment: 20

Ref country code: IE

Payment date: 20181210

Year of fee payment: 20

Ref country code: NL

Payment date: 20181213

Year of fee payment: 20

Ref country code: SE

Payment date: 20181211

Year of fee payment: 20

Ref country code: FI

Payment date: 20181210

Year of fee payment: 20

Ref country code: PT

Payment date: 20181213

Year of fee payment: 20

Ref country code: GR

Payment date: 20181112

Year of fee payment: 20

Ref country code: MC

Payment date: 20181128

Year of fee payment: 20

Ref country code: DE

Payment date: 20181204

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20181212

Year of fee payment: 20

Ref country code: CH

Payment date: 20181217

Year of fee payment: 20

Ref country code: FR

Payment date: 20181121

Year of fee payment: 20

Ref country code: BE

Payment date: 20181119

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20181220

Year of fee payment: 20

Ref country code: ES

Payment date: 20190102

Year of fee payment: 20

Ref country code: CY

Payment date: 20181211

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 69941629

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: EUP

Effective date: 20191214

REG Reference to a national code

Ref country code: NL

Ref legal event code: MK

Effective date: 20191213

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20191213

REG Reference to a national code

Ref country code: FI

Ref legal event code: MAE

REG Reference to a national code

Ref country code: BE

Ref legal event code: MK

Effective date: 20191214

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20191231

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20191213

REG Reference to a national code

Ref country code: IE

Ref legal event code: MK9A

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK07

Ref document number: 447398

Country of ref document: AT

Kind code of ref document: T

Effective date: 20191214

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20191214

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20200804

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20191215